Get Your Personalized Supplement StackSupplement Stack Quiz

Saccharomyces Boulardii

Also known as: Saccharomyces boulardii, S. boulardii, probiotic yeast, Florastor

Overview

Saccharomyces boulardii is a non-pathogenic yeast strain, originally isolated from lychee fruit, widely recognized and utilized as a probiotic supplement. Unlike many probiotics, it is not a bacterium but a yeast, offering unique advantages such as resistance to antibiotics. Its primary applications include the prevention and treatment of antibiotic-associated diarrhea (AAD) and Clostridium difficile-associated diarrhea, as well as serving as an adjunct therapy in Helicobacter pylori eradication. S. boulardii is heat-stable, ensuring its viability during processing and storage, and it effectively survives passage through the gastrointestinal tract, allowing it to exert its beneficial effects. The efficacy and safety of S. boulardii are supported by numerous randomized controlled trials and meta-analyses, establishing it as a well-researched and reliable probiotic option.

Benefits

Saccharomyces boulardii demonstrates significant efficacy in preventing antibiotic-associated diarrhea (AAD). Meta-analyses indicate a substantial reduction in AAD risk, with a relative risk of 0.47 (95% CI: 0.38–0.57), translating to a reduction in incidence from 18.7% to 8.5% (NNT = 10). It also reduces the risk of Clostridium difficile-associated diarrhea, although the effect sizes are less pronounced than for AAD. As an adjuvant to Helicobacter pylori eradication therapy, S. boulardii increases eradication rates by approximately 11%. Furthermore, it may reduce total adverse effects during H. pylori eradication therapy. These benefits are observed in both children and adults, making S. boulardii a versatile probiotic for various populations undergoing antibiotic treatment.

How it works

Saccharomyces boulardii exerts its probiotic effects through several mechanisms within the gastrointestinal tract. It modulates the gut microbiota by inhibiting the growth of pathogenic bacteria and fostering the proliferation of beneficial bacteria. Additionally, it enhances intestinal barrier function, reducing inflammation and preventing the translocation of harmful substances across the intestinal lining. S. boulardii produces enzymes and metabolites that directly inhibit pathogen growth, contributing to its antimicrobial activity. Its action is primarily localized to the gut, with minimal systemic absorption, ensuring targeted effects on the gastrointestinal environment.

Side effects

Saccharomyces boulardii is generally well-tolerated, with a low incidence of adverse effects. Common side effects are rare, but mild gastrointestinal symptoms such as bloating or flatulence may occur in some individuals. Uncommon side effects, reported in 1-5% of users, include mild GI discomfort. Rare side effects, occurring in less than 1% of cases, include fungemia, a bloodstream infection with yeast, primarily observed in immunocompromised or critically ill patients with central venous catheters. There are no significant drug interactions reported, and S. boulardii can be used concomitantly with antibiotics. However, it is contraindicated in patients with central venous catheters, severe immunosuppression, or a history of fungemia. Caution is advised when using S. boulardii in immunocompromised individuals to mitigate the risk of systemic infection.

Dosage

The minimum effective dose of Saccharomyces boulardii is typically 250–500 mg per day, corresponding to 5–10 billion CFU per day. An optimal dosage range is between 250–1000 mg per day (5–20 billion CFU/day). Doses up to 1000 mg/day are commonly used and generally considered safe. It is recommended to take S. boulardii during antibiotic therapy and continue for several days after completion to maximize its protective effects against antibiotic-associated diarrhea. S. boulardii is available in various forms, including capsules, powders, and sachets, all of which are effective. As it is not absorbed systemically, its effects are localized to the gut.

FAQs

When should I take Saccharomyces boulardii?

Take it daily during antibiotic therapy and for a few days after to reduce the risk of diarrhea and GI side effects. It should be taken with antibiotics to prevent antibiotic-associated diarrhea.

Is Saccharomyces boulardii safe for everyone?

It is safe for most populations, but avoid in immunocompromised individuals due to a rare risk of fungemia. It is not a substitute for medical treatment in severe infections.

What are the expected results from taking Saccharomyces boulardii?

Expect a reduced risk of diarrhea and GI side effects during antibiotic use. Efficacy is best established for antibiotic-associated diarrhea and H. pylori eradication.

Is Saccharomyces boulardii a cure for all GI disorders?

No, it is not a cure for all GI disorders. Its efficacy is best established for AAD and H. pylori eradication. It is not a substitute for medical treatment in severe infections.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/20458757/ – This study is a systematic review and meta-analysis that examines the efficacy of probiotics, including Saccharomyces boulardii, in preventing antibiotic-associated diarrhea (AAD). The review concludes that probiotics are effective in preventing AAD, with S. boulardii showing a significant reduction in the risk of developing diarrhea during antibiotic treatment.
https://pmc.ncbi.nlm.nih.gov/articles/PMC2868213/ – This article reviews the use of Saccharomyces boulardii as a biotherapeutic agent in the treatment and prevention of various gastrointestinal disorders. It highlights the mechanisms of action of S. boulardii, including its ability to modulate the gut microbiota, enhance intestinal barrier function, and exert anti-inflammatory effects, supporting its use in conditions like AAD and inflammatory bowel disease.
https://www.florastor.ca/en/healthcare-professionals/florastor-11-meta-analysis-explained.html – This resource explains the findings of a meta-analysis on Florastor (Saccharomyces boulardii) and its effectiveness in preventing antibiotic-associated diarrhea. The meta-analysis demonstrates that Florastor significantly reduces the risk of AAD in both children and adults, highlighting its clinical utility in patients undergoing antibiotic therapy.
https://onlinelibrary.wiley.com/doi/10.1111/apt.13344 – This meta-analysis evaluates the efficacy of Saccharomyces boulardii in preventing Clostridium difficile-associated diarrhea (CDAD). The study concludes that S. boulardii can reduce the risk of CDAD, particularly when used in conjunction with standard antibiotic treatment, suggesting its potential as an adjunctive therapy for preventing this infection.
https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2025.1441185/full – This meta-analysis investigates the impact of Saccharomyces boulardii on Helicobacter pylori eradication rates and adverse effects during eradication therapy. The findings indicate that S. boulardii increases H. pylori eradication rates and reduces the total adverse effects experienced by patients undergoing eradication therapy, supporting its use as an adjuvant treatment.